Overall CARM gets a fundamental rating of 0 out of 10. We evaluated CARM against 525 industry peers in the Biotechnology industry. CARM has a bad profitability rating. Also its financial health evaluation is rather negative. CARM is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CARM has reported negative net income.
In the past year CARM has reported a negative cash flow from operations.
CARM had negative earnings in each of the past 5 years.
CARM had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CARM has a Return On Assets of -985.18%. This is amonst the worse of the industry: CARM underperforms 97.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	-985.18%
ROE	N/A
ROIC	N/A

ROA(3y)-102.03%

ROA(5y)-64.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CARM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CARM has more shares outstanding
Compared to 5 years ago, CARM has more shares outstanding
CARM has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -119.93, we must say that CARM is in the distress zone and has some risk of bankruptcy.
CARM's Altman-Z score of -119.93 is on the low side compared to the rest of the industry. CARM is outperformed by 96.45% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-119.93

ROIC/WACCN/A

WACC10.79%

2.3 Liquidity

A Current Ratio of 0.48 indicates that CARM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.48, CARM is doing worse than 92.90% of the companies in the same industry.
CARM has a Quick Ratio of 0.48. This is a bad value and indicates that CARM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CARM (0.48) is worse than 92.34% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.48
Quick Ratio	0.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.71%, which is quite impressive.
CARM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.02%.
Measured over the past years, CARM shows a decrease in Revenue. The Revenue has been decreasing by -9.56% on average per year.

EPS 1Y (TTM)33.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%14.81%

Revenue 1Y (TTM)-48.02%

Revenue growth 3Y-9.56%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 11.28% on average over the next years. This is quite good.
CARM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.

EPS Next Y45.16%

EPS Next 2Y27.93%

EPS Next 3Y19.18%

EPS Next 5Y11.28%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARM. No positive earnings are expected for the next year.